Home/Filings/4/0000899243-20-020427
4//SEC Filing

NEWTYN PARTNERS, LP 4

Accession 0000899243-20-020427

CIK 0001274792other

Filed

Jul 23, 8:00 PM ET

Accepted

Jul 24, 6:59 PM ET

Size

22.3 KB

Accession

0000899243-20-020427

Insider Transaction Report

Form 4
Period: 2020-07-22
Transactions
  • Purchase

    Common Stock

    2020-07-22$3.04/sh+56,606$172,190796,365 total(indirect: See footnote)
  • Purchase

    Common Stock

    2020-07-22$3.20/sh+46,745$149,677739,759 total(indirect: See footnote)
  • Purchase

    Common Stock

    2020-07-22$3.04/sh+40,488$123,160580,515 total(indirect: See footnote)
  • Purchase

    Common Stock

    2020-07-22$3.20/sh+33,435$107,059540,027 total(indirect: See footnote)
Transactions
  • Purchase

    Common Stock

    2020-07-22$3.20/sh+46,745$149,677739,759 total(indirect: See footnote)
  • Purchase

    Common Stock

    2020-07-22$3.04/sh+40,488$123,160580,515 total(indirect: See footnote)
  • Purchase

    Common Stock

    2020-07-22$3.20/sh+33,435$107,059540,027 total(indirect: See footnote)
  • Purchase

    Common Stock

    2020-07-22$3.04/sh+56,606$172,190796,365 total(indirect: See footnote)
Transactions
  • Purchase

    Common Stock

    2020-07-22$3.04/sh+40,488$123,160580,515 total(indirect: See footnote)
  • Purchase

    Common Stock

    2020-07-22$3.20/sh+46,745$149,677739,759 total(indirect: See footnote)
  • Purchase

    Common Stock

    2020-07-22$3.04/sh+56,606$172,190796,365 total(indirect: See footnote)
  • Purchase

    Common Stock

    2020-07-22$3.20/sh+33,435$107,059540,027 total(indirect: See footnote)
Transactions
  • Purchase

    Common Stock

    2020-07-22$3.20/sh+33,435$107,059540,027 total(indirect: See footnote)
  • Purchase

    Common Stock

    2020-07-22$3.04/sh+56,606$172,190796,365 total(indirect: See footnote)
  • Purchase

    Common Stock

    2020-07-22$3.04/sh+40,488$123,160580,515 total(indirect: See footnote)
  • Purchase

    Common Stock

    2020-07-22$3.20/sh+46,745$149,677739,759 total(indirect: See footnote)
Levy Noah G.
DirectorOther
Transactions
  • Purchase

    Common Stock

    2020-07-22$3.04/sh+56,606$172,190796,365 total(indirect: See footnote)
  • Purchase

    Common Stock

    2020-07-22$3.04/sh+40,488$123,160580,515 total(indirect: See footnote)
  • Purchase

    Common Stock

    2020-07-22$3.20/sh+46,745$149,677739,759 total(indirect: See footnote)
  • Purchase

    Common Stock

    2020-07-22$3.20/sh+33,435$107,059540,027 total(indirect: See footnote)
Transactions
  • Purchase

    Common Stock

    2020-07-22$3.20/sh+46,745$149,677739,759 total(indirect: See footnote)
  • Purchase

    Common Stock

    2020-07-22$3.04/sh+56,606$172,190796,365 total(indirect: See footnote)
  • Purchase

    Common Stock

    2020-07-22$3.04/sh+40,488$123,160580,515 total(indirect: See footnote)
  • Purchase

    Common Stock

    2020-07-22$3.20/sh+33,435$107,059540,027 total(indirect: See footnote)
Footnotes (3)
  • [F1]The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
  • [F2]The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
  • [F3]The purchase of the securities referenced in this Form 4 were conducted in a private transaction between Gary Crocker and certain family members and affiliates as the sellers and each of Western Standard Partners, L.P., Western Standard Partners QP, L.P., Newtyn Partners, LP, and Newton Partners TE, LP as the purchasers. Gary Crocker is President and Chairman of Merrimack Pharmaceuticals, Inc. (the "Company"). Eric Andersen, a member of the Company's Board of Directors, is Managing Member of Western Standard LLC, the investment manager for each of Western Standard Partners L.P. and Western Standard Partners QP L.P. Noah Levy, a member of the Company's Board of Directors, is Managing Member of Newtyn Management, LLC, the investment manager for Newtyn Partners, LP, and Newton Partners TE, LP.

Issuer

MERRIMACK PHARMACEUTICALS INC

CIK 0001274792

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001548707

Filing Metadata

Form type
4
Filed
Jul 23, 8:00 PM ET
Accepted
Jul 24, 6:59 PM ET
Size
22.3 KB